摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[6-(3,4-Dichloro-phenoxy)-pyridin-3-yl]-(4-isopropyl-piperazin-1-yl)-methanone

中文名称
——
中文别名
——
英文名称
[6-(3,4-Dichloro-phenoxy)-pyridin-3-yl]-(4-isopropyl-piperazin-1-yl)-methanone
英文别名
[6-(3,4-dichlorophenoxy)-pyridin-3-yl]-(4-isopropylpiperazine-1-yl)-methanone;(6-(3,4-Dichlorophenoxy)pyridin-3-yl)(4-isopropylpiperazin-1-yl)methanone;[6-(3,4-dichlorophenoxy)pyridin-3-yl]-(4-propan-2-ylpiperazin-1-yl)methanone
[6-(3,4-Dichloro-phenoxy)-pyridin-3-yl]-(4-isopropyl-piperazin-1-yl)-methanone化学式
CAS
——
化学式
C19H21Cl2N3O2
mdl
——
分子量
394.301
InChiKey
CWVSGHVVKAFRPJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    26
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.37
  • 拓扑面积:
    45.7
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • Substituted pyridyl amide compounds as modulators of the histamine H3 receptor
    申请人:Janssen Pharmaceutica NV
    公开号:US07777031B2
    公开(公告)日:2010-08-17
    Processes are disclosed for making certain compounds of Formula (II): or their pharmaceutically active salts, that are histamine H3 receptor modulators useful in the treatment of histamine H3 receptor-mediated diseases. In one embodiment, the process comprises reacting a compound of formula (7-1): with a compound of formula (B3): in the presence of at least one equivalent of a first base, in a first organic solvent, to give a compound of Formula (II).
    揭示了制备公式(II)的某些化合物或其药物活性盐的工艺,这些化合物是组胺H3受体调节剂,可用于治疗组胺H3受体介导的疾病。在一种实施方式中,该工艺包括在第一有机溶剂中,在至少一个第一碱当量的存在下,将公式(7-1)的化合物与公式(B3)的化合物反应,以得到公式(II)的化合物。
  • PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS
    申请人:Janssen Pharmaceutica NV
    公开号:EP3216784A1
    公开(公告)日:2017-09-13
    The present invention is directed to novel processes for the preparation of histamine H3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and / or psychiatric disorders
    本发明涉及制备组胺 H3 受体调节剂的新工艺,用于治疗认知障碍、睡眠障碍和/或精神障碍等疾病。
  • Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: Identification of candidates for clinical development
    作者:Michael A. Letavic、Leah Aluisio、John R. Atack、Pascal Bonaventure、Nicholas I. Carruthers、Christine Dugovic、Anita Everson、Mark A. Feinstein、Ian C. Fraser、Kenway Hoey、Xiaohui Jiang、John M. Keith、Tatiana Koudriakova、Perry Leung、Brian Lord、Timothy W. Lovenberg、Kiev S. Ly、Kirsten L. Morton、S. Timothy Motley、Diane Nepomuceno、Michele Rizzolio、Raymond Rynberg、Kia Sepassi、Jonathan Shelton
    DOI:10.1016/j.bmcl.2010.05.041
    日期:2010.7
    The pre-clinical characterization of novel aryloxypyridine amides that are histamine H-3 receptor antagonists is described. These compounds are high affinity histamine H-3 ligands that penetrate the CNS and occupy the histamine H-3 receptor in rat brain. Several compounds were extensively pro. led pre-clinically leading to the identification of two compounds suitable for nomination as development candidates. (C) 2010 Elsevier Ltd. All rights reserved.
  • US7777031B2
    申请人:——
    公开号:US7777031B2
    公开(公告)日:2010-08-17
  • US8637520B2
    申请人:——
    公开号:US8637520B2
    公开(公告)日:2014-01-28
查看更多